News Europe recommends Tecentriq in bladder cancer, but efficacy ... The European Union’s CHMP committee recommended 11 medicines on Friday, including five orphan drugs.
News The week that turned the cancer immunotherapy market on its ... Contrasting fortunes for Roche and AZ in a week of drama.
News Drama as Roche's Tecentriq fails in key bladder cancer trial Roche has been shocked by the late-stage trial failure of its immunotherapy Tecentriq in bladder cancer, a setback which could cost it billions if the drug loses its licence.
News FDA approves new uses for two Roche drugs FDA hands out new indications for Tecentriq and Lucentis.
News Opdivo still clear immunotherapy leader despite Keytruda gai... Immunotherapy takes on rivals from Roche and BMS.
News Lilly bags FDA okay for Wegovy pill rival orforglipron Eli Lilly has claimed US approval for oral GLP-1 agonist orforglipron, setting up a market clash with Novo Nordisk's first-to-market Wegovy pill.
Sales & Marketing Sponsored Using AI-driven synthetic personas to take your insights fur... As AI continues to reshape the healthcare landscape, pharma teams are beginning to leverage synthetic personas.
